Health · Pharma & Biotech · 7 hrs ago

Marrow Therapeutics raises $173 million to develop sickle cell treatment

Marrow Therapeutics raises $173 million to develop sickle cell treatment

Marrow Therapeutics raised $173 million to develop treatments for severe blood diseases.

The startup, led by CEO Romesh Subramanian, is developing a lead drug called MAR-101 for sickle cell disease and beta thalassemia.

Current gene therapies can have long-lasting effects, but they require patients’ stem cells to be modified in a lab and chemotherapy before treatment.

They are also available only at specially equipped centers and cost millions of dollars, which has contributed to slow uptake.

MAR-101 is designed as an injection that delivers a small RNA molecule to bone marrow cells, prompting them to make fetal hemoglobin.

Marrow hopes the treatment can be as effective as gene therapy while being simpler to manufacture and access.

The company plans to use its funding to advance MAR-101 and build manufacturing capacity, but it has not said when clinical trials will begin.

3 sources

Related

What people are saying

Romesh SubramanianMarrow Therapeutics CEO
We expect it to be as good as [gene therapy] in patients
via STAT
but to be proven for sure.
via STAT